Last reviewed · How we verify

Lidocaine 1% Injectable Solution, Sufentanil

University of Saskatchewan · Phase 3 active Small molecule

This combination drug uses lidocaine as a local anesthetic to block nerve conduction and sufentanil as an opioid analgesic to provide pain relief through mu-opioid receptor activation.

This combination drug uses lidocaine as a local anesthetic to block nerve conduction and sufentanil as an opioid analgesic to provide pain relief through mu-opioid receptor activation. Used for Local anesthesia with systemic analgesia (specific indication in phase 3 trial not publicly detailed).

At a glance

Generic nameLidocaine 1% Injectable Solution, Sufentanil
Also known asOpioid-containing pre-intubation medications
SponsorUniversity of Saskatchewan
Drug classLocal anesthetic + opioid analgesic combination
TargetVoltage-gated sodium channels (lidocaine); mu-opioid receptor (sufentanil)
ModalitySmall molecule
Therapeutic areaPain Management / Anesthesia
PhasePhase 3

Mechanism of action

Lidocaine works by blocking sodium channels in nerve membranes, preventing the initiation and propagation of action potentials in sensory nerves. Sufentanil is a potent synthetic opioid agonist that binds to mu-opioid receptors in the central and peripheral nervous system to produce analgesia and sedation. Together, they provide both local and systemic pain control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: